Quantum Genomics Announces the Publication of Two

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
28
Quantum Genomics Announces the Publication of Two Scientific Articles Confirming the Efficacy of Firibastat for Heart Failure

PARIS and NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC) , a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, announces the publication of two new scientific articles on the efficacy of firibastat in Journal of Molecular and Cellular Cardiology and Journal of Cardiovascular Pharmacology. Firibastat is the first central acting aminopeptidase A inhibitor (BAPAI) to be studied in preclinical experimental models of heart failure. These new publications come as the company launches QUORUM, a Phase IIb study evaluating the safety and efficacy of firibastat compared to ramipril in patients following acute myocardial infarction.

  1. The article entitled “ Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction ” published by the Journal of Cardiovascular Pharmacology presents the results of a study conducted at the University of Ottawa Heart Institute in collaboration with the laboratory directed by Pr. Frans Leenen and the INSERM laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France. It examined the effects of firibastat in rats after myocardial infarction (DOI: 10.1097/FJC.0000000000000638). This study demonstrated that repeated oral administration of firibastat reduced cardiac dysfunction after myocardial infarction as effectively as losartan, an angiotensin II receptor type1 antagonist chosen as a reference treatment. However, unlike losartan, it did not induce hypotension or increase the risk of degrading renal function.
  1. The article entitled “ Brain renin-angiotensin system blockade with orally active aminopeptidase A inhibitor prevents cardiac dysfunction after myocardial infarction in mice” published by the Journal of Molecular and Cellular Cardiology presents the results of a study conducted in collaboration with the INSERM laboratory directed by Dr. Catherine Llorens-Cortès at the Collège de France. The work examined the effects of chronic oral treatment with firibastat in mice after myocardial infarction. (DOI: 10.1016/j.yjmcc.2018.12.008). The study showed that firibastat administered orally for four or eight weeks to mice within 48 hours after myocardial infarction is at least as effective as enalapril, an angiotensin I converting enzyme inhibitor that is clinically approved for preventing and treating symptomatic heart failure. Firibastat treatment prevents cardiac dysfunction by normalizing brain aminopeptidase A hyperactivity and attenuates cardiac hypertrophy and fibrosis observed after a myocardial infarction.

“We are pleased to see the promising results observed in our preclinical trials of firibastat in heart failure confirmed by our peers,” said Fabrice Balavoine, VP of Research and Development. “Firibastat and central acting aminopeptidase A inhibitors constitute a new class of brain renin-angiotensin system blockers potentially capable of improving prevention and treatment of heart failure after myocardial infarction. The recent publications of firibastat’s efficacy in these high-quality journals is very encouraging for this class of therapeutics and the Company as we advance this candidate through the QUORUM Phase IIb study.”

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).

Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC).

For more information, please visit www.quantum-genomics.com , or follow us on Twitter and LinkedIn

Contact information

Quantum Genomics  
Jean-Philippe Milon CEO +33 (0)1 85 34 77 70 | jean-philippe.milon@quantum-genomics.com Marc Karako CFO - Investor Relations +33 (0)1 85 34 77 70 | marc.karako@quantum-genomics.com
   
So Bang (Europe)  
Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.fr Samuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | samuel @so-bang.fr
   
LifeSci (USA)  
Dan Ferry Financial Communications +1 (617) 535-7746 |  Daniel@lifesciadvisors.com Michael Tattory Media Relations and Scientific Communications +1 (646) 751-4362 | mtattory@lifescipublicrelations.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Endurance Energy's Modular Tech Revs Up Southeast Asia

Updated Category News Views 4

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 3

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 3

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 4

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 4

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Farm Aid 2026: A Resilient Tribute to Family Farmers

Updated Category News Views 10

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Continue Reading
China Southern Airlines Marks 70th Anniversary in NYC

Updated Category News Views 4

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Continue Reading
Cut Winter Heating Costs with Townsend's Rebate Help

Updated Category News Views 9

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 5

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 4

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading

Top 5 Most Recently Viewed Articles

Zero Networks Welcomes New Leadership Driving Innovation

Updated Category News Views 307

Zero Networks Expands Leadership Team to Bolster Growth Zero Networks, a pioneer in zero trust security solutions, is excited to announce the addition of three new leaders to its team. These appointments aim to enhance product innovation and operational efficiency. Albert Estevez Polo has been named as Field CTO, while Moshe Strenger takes on the role of Vice President of...

Continue Reading
Matthew M. Caverly, PhD: A Pinnacle of Excellence in Academia

Updated Category News Views 180

Celebrating Academic Excellence In the realm of academic achievement, Dr. Matthew M. Caverly, PhD, has recently been recognized as a Pinnacle Professional Member by The Inner Circle. This esteemed acknowledgment is a testament to his significant contributions to political science education, particularly at a leading educational institution. Contributions to Education Dr....

Continue Reading
Market Sentiment Shifts: Analyzing QuantumScape's Short Interest

Updated Category News Views 193

Market Moves: The Short Interest Dilemma Jumping into today's fray with QuantumScape Corp (NYSE:QS) and their rising short interest—now sitting at a troublesome 12.87% of available shares. That's 62.92 million shares sold short, pushing the total up by over three and a half percent since the last reporting. What does this tell us? Traders are either paving the way for a...

Continue Reading
Embracing Technology for a Promising Restaurant Future

Updated Category News Views 341

Embracing Technology for a Promising Restaurant Future The restaurant franchise industry has faced numerous challenges over the last five years. However, optimism is rising, largely thanks to the integration of digital solutions, enhanced creativity in menus, and advances in artificial intelligence (AI). A recent survey by TD Bank highlights the expectations of restaurant...

Continue Reading
UPAY Inc. Champions Microfinance Sector Through ACPAS Support

Updated Category News Views 111

UPAY Inc. Champions the Microfinance Sector Through ACPAS Support UPAY Inc. (OTCQB: UPYY) proudly announces that its subsidiary, ACPAS, has sponsored an important Compliance Workshop for microfinance professionals. This event took place at a prominent venue, gathering key figures from the industry to discuss vital topics related to compliance and regulatory practices. The...

Continue Reading